NCT05147467 2026-03-27Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLAscentage Pharma Group Inc.Phase 2 Recruiting75 enrolled
NCT04496349 2025-11-04A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLAscentage Pharma Group Inc.Phase 2 Recruiting78 enrolled